Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
Holding AQST?
Track your performance easily
AQST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.41 - $6.23
Previous Close$5.49
Volume1.22M
Average Volume (3M)1.25M
Market Cap
$499.92M
Enterprise Value$433.24M
Total Cash (Recent Filing)$89.87M
Total Debt (Recent Filing)$23.19M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 04, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding91,059,760
10 Day Avg. Volume1,387,609
30 Day Avg. Volume1,253,113
Standard Deviation0.33
R-Squared0.20
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-14.08
Price to Sales (P/S)8.57
Price to Cash Flow (P/CF)-17.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.42
Enterprise Value/Gross Profit14.56
Enterprise Value/Ebitda-45.94
Forecast
1Y Price Target
$10.33Price Target Upside82.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Aquestive Therapeutics News
PremiumCompany Announcements
Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study
PremiumCompany Announcements
Aquestive Therapeutics Showcases Innovations and Market Strategy
PremiumCompany Announcements
Aquestive Therapeutics Outlines Growth and Product ProgressOwnership Overview
3.96% Insiders
8.51% Mutual Funds
1.22% Other Institutional Investors
77.61% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $1.41 and its highest was $6.23 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Currently, no data Available
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Nov 04, 2024 which is in 5 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Aug 06, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.115 by $0.085.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -$0.12.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 91,059,760 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.115. Following the earnings report the stock price went up 0.882%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Among the largest hedge funds holding Aquestive Therapeutics’s share is Woodline Partners LP. It holds Aquestive Therapeutics’s shares valued at 2M.
---
Aquestive Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (82.51% Upside)
$10.33 (82.51% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 146.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
286.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
106.35%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
---
AQST Company Deck
---
AQST Earnings Call
Q2 2024
0:00 / 0:00
---
AQST Stock 12 Month Forecast
Average Price Target
$10.33
▲(82.51% Upside)
Technical Analysis
Best Analysts Covering AQST
1 Year
1 Year Success Rate
16/17 ratings generated profit
1 Year Average Return
+98.89%
reiterated a buy rating 5 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +98.89% per trade.
---